HIGHLIGHTS
SUMMARY
Initially approved only in patients with relapsed/refractory (R/R) and deletion 17p (del 17p) CLL, ibrutinib was later endorsed as first-line therapy for all CLL patients and soon followed by other oral mechanism-driven drugs (e_g, idelalisib, venetoclax, acalabrutinib). This real-world analysis aims to evaluate the clinical outcomes, the incidence of AEs, discontinuation rate, prognostic factors, and disease characteristics of CLL patients receiving ibrutinib as a single-agent therapy. The authors carried out a single-center observational retrospective study of one hundred twenty-three adult patients diagnosed with CLL and small . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.